Ionis Pharmaceuticals Inc

Key Statistics

Recent News

• 10 Health Care Stocks With Whale Alerts In Today’s Session Benzinga

  This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity sca

• Arrowhead: Stock Up On SHTG Data - No Ceiling On Valuation Growth Potential SeekingAlpha

  Arrowhead Pharmaceuticals, Inc. jumped on Phase 3 plozasiran sHTG data; see key catalysts, risks, and upside vs Ionis ahead of filings. Click for this ARWR update.

• Arrowhead Pharmaceuticals: Redemplo Meets High Expectations In SHTG Trials SeekingAlpha

  Arrowhead Pharmaceuticals reported positive phase 3 results for Redemplo, achieving 79-81% triglyceride reductions. Click here to read an analysis of ARWR stock now.

• Biogen And The Limitation Of The Tau Approach To Alzheimer's Disease SeekingAlpha

  Biogen’s (BIIB) FDA-approved injectable Leqembi cuts infusion costs but risks brain bleeds; see how diranersen compares and why neither may boost valuation.

• Tracking Baker Brothers Portfolio: Q1 2026 Update SeekingAlpha

  Baker Brothers’ Q1 2026 13F: $17.42B biotech portfolio, top holdings & key buys/sells. Click here to read more.

• Guggenheim Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $89 Benzinga

  Guggenheim analyst Brad Canino maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $106 to $89.